231 related articles for article (PubMed ID: 26824415)
1. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
2. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z
Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.
Fan R; Wang Y; Wang Y; Wei L; Zheng W
Am J Transl Res; 2017; 9(3):1483-1491. PubMed ID: 28386373
[TBL] [Abstract][Full Text] [Related]
5. AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.
Badmann S; Mayr D; Schmoeckel E; Hester A; Buschmann C; Beyer S; Kolben T; Kraus F; Chelariu-Raicu A; Burges A; Mahner S; Jeschke U; Trillsch F; Czogalla B
Sci Rep; 2022 Feb; 12(1):1862. PubMed ID: 35115586
[TBL] [Abstract][Full Text] [Related]
6. Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.
Beranič N; Lanišnik Rižner T
Chem Biol Interact; 2013 Feb; 202(1-3):218-25. PubMed ID: 23183084
[TBL] [Abstract][Full Text] [Related]
7. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
10. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
Zhang Z; Dong L; Sui L; Yang Y; Liu X; Yu Y; Zhu Y; Feng Y
Int J Gynecol Cancer; 2011 Feb; 21(2):213-21. PubMed ID: 21270604
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
12. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
[TBL] [Abstract][Full Text] [Related]
13. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
Banno K; Kisu I; Yanokura M; Tsuji K; Masuda K; Ueki A; Kobayashi Y; Yamagami W; Nomura H; Susumu N; Aoki D
Int J Oncol; 2012 Jun; 40(6):1755-62. PubMed ID: 22366992
[TBL] [Abstract][Full Text] [Related]
14. [Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
Niu YJ; Shi HR; Xie Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):135-40. PubMed ID: 26917483
[TBL] [Abstract][Full Text] [Related]
15. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
[TBL] [Abstract][Full Text] [Related]
16. LASS2 mediates Nrf2-driven progestin resistance in endometrial cancer.
Yang B; Hu M; Fu Y; Sun D; Zheng W; Liao H; Zhang Z; Chen X
Am J Transl Res; 2021; 13(3):1280-1289. PubMed ID: 33841656
[TBL] [Abstract][Full Text] [Related]
17. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
[TBL] [Abstract][Full Text] [Related]
18. High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
Jiang T; Chen N; Zhao F; Wang XJ; Kong B; Zheng W; Zhang DD
Cancer Res; 2010 Jul; 70(13):5486-96. PubMed ID: 20530669
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
[TBL] [Abstract][Full Text] [Related]
20. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
